Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure

Ovid Technologies (Wolters Kluwer Health) - Tập 94 Số 11 - Trang 2807-2816 - 1996
Michael R. Bristow1, Edward M. Gilbert1, William T. Abraham1, Kirkwood F. Adams1, Michael B. Fowler1, Ray E. Hershberger1, Spencer H. Kubo1, Kenneth A. Narahara1, Henry Ingersoll1, Steven K. Krueger1, Sarah Young2,1, Neil H. Shusterman2,1
1the University of Colorado Health Sciences Center, Denver (M.R.B., W.T.A.), University of Utah Health Sciences Center (E.M.G.), University of North Carolina at Chapel Hill (K.F.A.), Stanford University Hospital, Palo Alto, Calif (M.B.F.), Oregon Health Sciences Center, Portland (R.E.H.), University of Minnesota, Minneapolis (S.H.K.), University of California at Los Angeles Medical Center (K.A.N.), Sharp-Reese Stealy Medical Clinic, San Diego, Calif (H.I.), Nebraska Heart Institute, Lincoln (S.K.),...
2(GlaxoSmithKline)

Tóm tắt

Background We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a “third-generation” β-blocking agent with vasodilator properties, in chronic heart failure. Methods and Results Three hundred forty-five subjects with mild to moderate, stable chronic heart failure were randomized to receive treatment with placebo, 6.25 mg BID carvedilol (low-dose group), 12.5 mg BID carvedilol (medium-dose group), or 25 mg BID carvedilol (high-dose group). After a 2- to 4-week up-titration period, subjects remained on study medication for a period of 6 months. The primary efficacy parameter was submaximal exercise measured by two different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test. Carvedilol had no detectable effect on submaximal exercise as measured by either technique. However, carvedilol was associated with dose-related improvements in LV function (by 5, 6, and 8 ejection fraction [EF] units in the low-, medium-, and high-dose carvedilol groups, respectively, compared with 2 EF units with placebo, P< .001 for linear dose response) and survival (respective crude mortality rates of 6.0%, 6.7%, and 1.1% with increasing doses of carvedilol compared with 15.5% in the placebo group, P< .001). When the three carvedilol groups were combined, the all-cause actuarial mortality risk was lowered by 73% in carvedilol-treated subjects ( P <.001). Carvedilol also lowered the hospitalization rate (by 58% to 64%, P= .01) and was generally well tolerated. Conclusions In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose-related reductions in mortality and hospitalization rate.

Từ khóa


Tài liệu tham khảo

10.1016/0002-9343(63)90118-9

10.1056/NEJM198207223070401

10.1016/S0002-9149(84)80208-8

10.1161/circ.73.4.3948363

10.1016/0022-2828(85)90007-0

10.1161/circ.85.2.1370925

10.1016/S0046-8177(70)80007-7

10.1161/circ.92.8.2183

10.1056/NEJM198703263161307

10.1056/NEJM198409273111303

10.1056/NEJM199111213252103

10.1016/0140-6736(90)91517-E

10.1016/0002-9343(90)90146-5

10.1016/0002-9149(90)90488-M

10.1161/circ.82.2.1973638

10.1016/0735-1097(93)90230-X

10.1016/0735-1097(95)00012-S

10.1161/circ.92.6.1499

10.1016/0140-6736(93)92930-R

10.1016/0735-1097(94)90114-7

10.1016/0735-1097(94)90174-0

10.1161/circ.89.4.7908610

Bristow MR Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(suppl F):20-31.

Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.

10.1093/eurheartj/17.suppl_B.8

Bristow MR Larrabee P Minobe W Roden R Skerl L Klein J Handwerger D Port JD Mu¨ller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl 1):S68-S80.

Bristow MR, Larrabee P, Mu¨ller-Beckmann B, Minobe W, Roden R, Skerl RL, Klein J, Handwerger D. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest. 1992;70:S105-S113.

Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1991;17:142A. Abstract.

10.1161/circ.80.3.2548768

10.1161/circ.88.4.8104738

Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.

Sparrow J, Parameshwar J, Poole-Wilson PA. Assessment of functional capacity in chronic heart failure: time-limited exercise on a self-powered treadmill. Br Heart J. 1996;71:391-394.

10.1016/0002-8703(92)90986-6

10.1056/NEJM199209033271001

10.1161/circ.94.9.2285

10.1016/0002-9149(66)90071-3

Gilbert EM Abraham WT Olsen S Hattler B White M Mealy P Larrabee P Bristow MR. Comparative hemodynamic LV functional and anti-adrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation. In press.

10.1161/circ.79.3.2537158

10.1161/circ.90.4.7923660

10.1056/NEJM199605233342101

Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feurstein R, Gu J-L, Lsko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.

10.1016/S0002-9149(99)80228-8

10.1056/NEJM198706043162301

10.1093/oxfordjournals.eurheartj.a014671

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 94 Số 11

2807-2816

Thông tin tác giả